Prostatype Genomics AB — Investor Relations & Filings

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. This test, also known as the Prostatype Genomic Classifier (PGC), is designed for patients with a localized prostate cancer diagnosis. It provides a comprehensive assessment of the cancer's aggressiveness, serving as a decision support tool for clinicians and patients to determine the most appropriate treatment path. The Prostatype® test system utilizes biopsy tissue obtained at diagnosis to analyze the expression of three specific genes. This genetic information is then combined with established clinical parameters (PSA, Gleason Score, and Tumor Stage) to calculate a P-score, which indicates the risk of cancer-specific mortality. The primary objective is to reduce the risks of over- and under-treatment, thereby enhancing patient quality of life and contributing to more efficient use of healthcare resources.